LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Kodu・Aktsiate loetelu・Innoviva Inc

Innoviva Inc

Suletud

SektorTervishoid

20.63 -1.76

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.58

Max

21.03

Põhinäitajad
By Trading Economics
Sissetulek	26M 90M
Müük	7.5M 108M
P/E Sektori keskmine	13.374 80.03
Aktsiakasum	0.385
Kasumimarginaal	83.403
Töötajad	127
EBITDA	25M 108M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+52.38% upside

Turustatistika
By TradingEconomics
Turukapital	519M 1.7B
Eelmine avamishind	22.39
Eelmine sulgemishind	20.63

Uudiste sentiment

By Acuity

50%

23 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

18.57 / 18.75 Toetus ja vastupanu

Innoviva Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. dets 2025, 22:13 UTC

Tulu

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9. dets 2025, 21:40 UTC

Tulu

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9. dets 2025, 18:51 UTC

Omandamised, ülevõtmised, äriostud

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9. dets 2025, 16:57 UTC

Suurimad hinnamuutused turgudel

Clear Secure Rises on Medicare Identity Verification Contract

9. dets 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9. dets 2025, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Legend Holdings Stake in Lenovo Now at 32.34%

9. dets 2025, 23:45 UTC

Omandamised, ülevõtmised, äriostud

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9. dets 2025, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9. dets 2025, 23:43 UTC

Omandamised, ülevõtmised, äriostud

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9. dets 2025, 23:43 UTC

Omandamised, ülevõtmised, äriostud

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9. dets 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9. dets 2025, 22:42 UTC

Tulu

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9. dets 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. dets 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9. dets 2025, 21:36 UTC

Tulu

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9. dets 2025, 21:36 UTC

Tulu

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9. dets 2025, 21:36 UTC

Tulu

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9. dets 2025, 21:36 UTC

Tulu

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9. dets 2025, 21:36 UTC

Tulu

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9. dets 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9. dets 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9. dets 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Teck Reports Voting Results From Special Meeting of Hldrs

9. dets 2025, 20:26 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9. dets 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9. dets 2025, 19:52 UTC

Tulu

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9. dets 2025, 19:17 UTC

Tulu

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. dets 2025, 17:11 UTC

Tulu

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Innoviva Inc Prognoos

Hinnasiht

By TipRanks

52.38% tõus

12 kuu keskmine prognoos

Keskmine 32 USD 52.38%

Kõrge 45 USD

Madal 17 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Innoviva Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Innoviva Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

18.57 / 18.75Toetus ja vastupanu

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

23 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.